
- Genitourinary (Issue 3)
Dr. Neal Shore on Lack of Corticosteroid-Associated Adverse Events with Prednisone Plus Abiraterone
Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).
Neal Shore, MD, medical director of Carolina Urologic Research Center, discusses corticosteroid-associated adverse events with low-dose prednisone given with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC).
To better understand side effects associated with abiraterone plus prednisone, investigators looked at patients in two large global phase III trials, COU-AA-301 and COU-AA-302. Patients in both studies received either the combination or prednisone alone for treatment of mCRPC, explains Shore.
Investigators determined that the difference between those patients who received abiraterone plus prednisone twice a day versus those who just received prednisone were completely inconsequential when it came to hyperglycemia, weight gain, or weight increase, says Shore.
Articles in this issue
almost 10 years ago
Dr. Charles Ryan on Abiraterone Acetate in Elderly mCRPC Patientsalmost 10 years ago
HIFU Study Makes Case for Role in Prostate Cancer Subgroupalmost 10 years ago
Combination Therapy Reduces Bone Pain, Improves QoL in Metastatic CRPCalmost 10 years ago
Negotiation Training Improves Active Surveillance Participationalmost 10 years ago
New Analysis of Screening Data Questions Current USPSTF PSA Recommendationsalmost 10 years ago
Abiraterone Effective, Tolerable in Difficult-to-Treat mCRPC Populations






























